ENT & Ophthalmology drugs

56 results

  • acthar

    (Repository Corticotropin)
    Mallinckrodt ARD LLC
    Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.

  • alphagan p

    (brimonidine tartrate)
    Allergan, Inc.
    ALPHAGAN P (brimonidine tartrate ophthalmic solution) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

  • alrex

    (loteprednol etabonate)
    Bausch & Lomb Incorporated
    ALREX ophthalmic suspension is indicated for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis.

  • amjevita

    (adalimumab-atto)
    Amgen Inc
    AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

  • beovu

    (brolucizumab)
    Novartis Pharmaceuticals Corporation
    BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

  • botox

    (onabotulinumtoxinA)
    Allergan, Inc.
    BOTOX is indicated for treating overactive bladder, neurogenic detrusor overactivity in pediatric patients, chronic migraine prophylaxis, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, and blepharospasm/strabismus associated with dystonia in patients aged 12 and older. It is meant for those unresponsive or intolerant to anticholinergic medications.

  • bromsite

    (bromfenac)
    Sun Pharmaceutical Industries, Inc.
    BromSite (bromfenac ophthalmic solution) 0.075% is indicated for treating postoperative inflammation and preventing ocular pain in patients who have undergone cataract surgery.

  • byooviz

    (ranibizumab-nuna)
    BIOGEN INC.
    BYOOVIZ is indicated for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) in patients.

  • cequa

    (cyclosporine)
    Sun Pharmaceutical Industries, Inc.
    CEQUA ophthalmic solution is indicated for increasing tear production in patients with keratoconjunctivitis sicca (dry eye) as a calcineurin inhibitor immunosuppressant.

  • cimerli

    (ranibizumab-eqrn)
    Coherus BioSciences Inc
    CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.